London-based deep-tech startup Apoha emerged from stealth on June 3, 2026, after securing $36 million [1] in Series A funding.
This development represents a shift in how pharmaceutical, food, and materials companies design products. By simulating how molecules behave in real-world conditions, companies can potentially reduce the cost and time associated with physical laboratory failures.
The funding round was led by the venture-capital firm Singular [2]. Apoha said it intends to use the capital to develop a specialized AI framework the company calls “Liquid State Intelligence” [1]. This technology aims to create machines that can simulate human-like senses, including feel, taste, and smell [3].
According to the company, these models will predict how molecules behave under various conditions [1]. This capability is designed to provide scalable insights into the behavior of matter, which is often a bottleneck in the development of new drugs and materials [1].
Apoha is headquartered in London, United Kingdom [3]. The startup is positioning its platform as a tool to accelerate the discovery of new materials by predicting molecular failures before they occur in a physical setting [1].
By offering a digital alternative to traditional trial-and-error testing, the firm seeks to lower the barrier for innovation in the chemical and biological sectors [1]. The company said it did not provide further details on its specific client list or the current stage of its software deployment.
“Apoha emerged from stealth on June 3, 2026, after securing $36 million in Series A funding.”
The emergence of 'Liquid State Intelligence' suggests a move toward 'digital twins' for chemistry, where the sensory experience of a product can be modeled computationally. If Apoha can accurately simulate taste and smell, it could disrupt the R&D cycles of the flavor, fragrance, and pharmaceutical industries by shifting the heaviest part of the discovery process from the wet lab to the server.
